XOLAIR (omalizumab)

150 mg/mL subcutaneous syringe

• Inject 150 mg by subcutaneous route every 4 weeks

75 mg/0.5 mL subcutaneous syringe

• Inject 75 mg by subcutaneous route every 4 weeks

150 mg subcutaneous solution

• Inject 1.2 milliliters (150 mg) by subcutaneous route every 4 weeks

Chronic idiopathic urticaria

• Inject 150 mg by subcutaneous route every 4 weeks

• Inject 75 mg by subcutaneous route every 4 weeks (to be injected witha 150 mg syringe for a total dose of 225 mg)

• Inject 1.2 milliliters (150 mg) by subcutaneous route every 4 weeks

• Inject 1 milliliter (150 mg) by subcutaneous route every 4 weeks

• Inject 2.4 milliliters (300 mg) by subcutaneous route every 4 weeks divided into 2 doses and given at 2 different injection sites

• Inject 2 milliliters (300 mg) by subcutaneous route every 4 weeks (rotate sites)

• Inject 300 mg by subcutaneous route every 4 weeks (rotate sites)

Refractory extrinsic asthma

• Inject 75 mg by subcutaneous route every 2 weeks

• Inject 75 mg by subcutaneous route every 4 weeks

• Inject 150 mg by subcutaneous route every 2 weeks

• Inject 150 mg by subcutaneous route every 4 weeks

• Inject 0.5 milliliter (75 mg) by subcutaneous route every 2 weeks

• Inject 0.5 milliliter (75 mg) by subcutaneous route every 4 weeks

• Inject 150 mg by subcutaneous route every 2 weeks (to be injected with a 75 mg syringe for a total dose of 225 mg)

• Inject 150 mg by subcutaneous route every 4 weeks (to be injected with a 75 mg syringe for a total dose of 225 mg)

• Inject 300 mg by subcutaneous route every 2 weeks (to be injected with a 75 mg syringe for a total dose of 375 mg)

• Inject 300 mg by subcutaneous route every 4 weeks (to be injected with a 75 mg syringe for a total dose of 375 mg)

• Inject 75 mg by subcutaneous route every 2 weeks (to be injected witha 150 mg syringe for a total dose of 225 mg)

• Inject 75 mg by subcutaneous route every 4 weeks (to be injected witha 150 mg syringe for a total dose of 225 mg)

• Inject 75 mg by subcutaneous route every 2 weeks (to be injected withtwo 150 mg syringes for a total dose of 375 mg)

• Inject 75 mg by subcutaneous route every 4 weeks (to be injected withtwo 150 mg syringes for a total dose of 375 mg)

• Inject 1 milliliter (150 mg) by subcutaneous route every 2 weeks

• Inject 1.2 milliliters (150 mg) by subcutaneous route every 4 weeks

• Inject 1 milliliter (150 mg) by subcutaneous route every 4 weeks

• Inject 1.8 milliliters (225 mg) by subcutaneous route every 2 weeks divided into 2 doses and given at 2 different injection sites

• Inject 2.4 milliliters (300 mg) by subcutaneous route every 2 weeks divided into 2 doses and given at 2 different injection sites

• Inject 2.4 milliliters (300 mg) by subcutaneous route every 4 weeks divided into 2 doses and given at 2 different injection sites

• Inject 3 milliliters (375 mg) by subcutaneous route every 2 weeks using 3 separate injection sites. Do not administer more than 150 mg per injection site.